Market Intelligence

Access the latest earnings reports, market analysis, hot topics, and individual stock insights

Report Categories

View All

Recent Articles

View All
Malaysian Startup Seeks to Bring LabGrown Unagi to Market AIDriven Shift BlueCollar Skilled Trades Gain as EntryLevel WhiteCollar Jobs Slow Klarna Partners With EZContacts to Expand Flexible Payment Options in the Vision Care Sector Este Lauder Shares Jump in Premarket After Puig Merger Talks Terminate Mexico Agrees to Host Irans World Cup Squad Amid USIran Tensions Says President Sheinbaum ABTC Q1 2026 Earnings Earnings Miss Amid Significant EPS Surprise Revenue Absent DXC Q1 2026 Earnings EPS Surpasses Estimates as Cost Actions Drive Profitability INCY Q1 2026 Earnings Strong Earnings Beat Driven by Robust Pipeline Progress UHAL Q1 2026 Earnings Significant EPS Miss Despite Modest Stock Gain ASR Q1 2026 Earnings EPS Falls Short of Estimates Amid Operational Headwinds HCM III Acquisition Corp Warrants HCMAW Edge Higher Support Holds as SPAC Warrant Gains 35 General Motors GM Surges Over 5 as Investor Sentiment Strengthens Dyne Therapeutics DYN Holds Steady at 1737 as Traders Eye Key Support and Resistance Levels Galapagos NV GLPG Holds Steady Near Resistance Consolidation or Catalyst Ahead Balcony Solar Adoption Rises as US Residential Energy Costs Climb 30 Since 2020 Plus500 Reports 11 Revenue Growth in Latest Quarter Reaffirms FullYear Guidance Prolonged Impact US Fuel Prices Unlikely to Normalize This Year Even with Iran Peace Deal Market Movers LIC Campus Activewear Gain RVNL Pine Labs Slip After Earnings Government Plans Major Overhaul of Tax Administration to Ensure Smooth GST Rollout DWave Systems Stock Surges 44 Following Government Support Announcement Professional Title Red Cat Holdings Stock Surges on Positive Market Sentiment Pope Leos AI Critique Stirs Debate Anthropics Presence Signals Industry Engagement Shell SHEL Price Target Raised Following ARC Resources Acquisition Analysts Cite Synergies Immunic Appoints Erik Lundgren as CEO Amid Progress in Phase 3 Multiple Sclerosis Trials